Akebia amends bylaws to update proxy rules, stockholder meeting procedures

Akebia Therapeutics, Inc.

Eliminates requirement to provide stockholder list during actual meeting.
Addresses adjournment of meetings due to technical failure in remote communication.
Enhances disclosure requirements for stockholder nominations under universal proxy rules.
Imposes compliance deadlines and consequences for non-compliance with Rule 14a-19.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Akebia Therapeutics, Inc.: Board approved amendment and restatement of bylaws, eliminating stockholder list availability requirement at meeting, addressing remote meeting adjournment due to technical failure, and revising procedural mechanics under universal proxy rules (effective 2023-04-27).

Change: bylaw amendment
Effective: 2023-04-27

Exact text from the filing

On April 27, 2023, the Board of Directors (the “Board”) of Akebia Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Second Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-124259

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.